Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– TERLIVAZ ® (terlipressin) is the only FDA approved treatment for adults with HRS with rapid reduction in kidney function1 – DUBLIN , May 5, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, is pleased to announce it has received an award from the National Organization for Rare Disorders (NORD), recognizing it as an "Industry Innovator" for the creation of a treatment "to improve the lives of rare disease patients." Mallinckrodt is being recognized for the U.S. Food and Drug Administration (FDA) approval of TERLIVAZ ® (terlipressin) for injection for the treatment of adults with HRS with rapid reduction in kidney function.1  TERLIVAZ, the first and only FDA-approved product indicated for the treatment of adults with Hepatorenal Syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization,2 was approved for use on September 14, 2022.

Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company's Board of Directors, given their failure to provide any response to BHG's March 17, 2023, open letter, which extensively outlaid – after extensive investigation – an evidential.

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment Scheme

DUBLIN , April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.  A conference call for investors will begin at 8:30 a.m.

Mallinckrodt to Report Earnings Results for First Quarter 2023

WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public.

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

NEW YORK , April 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Mallinckrodt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK

NEW YORK , March 27, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Mallinckrodt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

NEW YORK , March 21, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Mallinckrodt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

LOS ANGELES--(BUSINESS WIRE)---- $MNK #MNK--The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses to Contact the Firm

– Findings from a retrospective analysis suggest that treatment with Acthar Gel is associated with significant reductions in corticosteroid use compared to other fourth-line alternatives for patients with advanced sarcoidosis1 – DUBLIN , March 21, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that an abstract highlighting results from a retrospective analysis evaluating the corticosteroid-sparing effect and reduction of corticosteroid burden of Acthar® Gel (repository corticotropin injection) therapy in patients with advanced sarcoidosis,1 has been selected for a poster presentation at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting taking place in San Antonio, Texas from March 21-24, 2023.    Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.

Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mallinckrodt plc and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $MNK #MNK--WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Mallinckrodt plc (NYSE American: MNK) resulting from allegations that Mallinckrodt may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation – MNK

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK) today issued an open letter (the “Letter”) to the Company's board of directors and executives regarding BHG's extensive investigation.

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding $2B Concealment of Asset Value Depreciation Expenses, Releases Full Analysis to SEC and U.S. Senate Finance Committee

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to U.S.

Buxton Helmsley Issues Letter to U.S. Senators Warren and Whitehouse Related to Mallinckrodt Plc. $2B Concealment of Asset Value Depreciation Expenses

Mallinckrodt plc (NYSE:MNK ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller and Chief Investor Relations Officer Sigurdur Olafsson - President and Chief Executive Officer Bryan Reasons - Executive Vice President and Chief Financial Officer Conference Call Participants Rishi Parekh - JP Morgan Brendan Hall - Brean Asset Management LLC Operator Good day, and thank you for standing by. Welcome to the Mallinckrodt Q4 2022 Earnings Announcement.

Mallinckrodt plc (MNK) Q4 2022 Earnings Call Transcript

Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN , Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022.

Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance

DUBLIN , Feb. 16, 2023 /PRNewswire/ --  Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time.

Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference

DUBLIN , Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023.  A conference call for investors will begin at 8:30 a.m.

Mallinckrodt to Report Earnings Results for Fourth Quarter 2022

– Findings from a retrospective analysis suggest that patients with baseline acute-on-chronic liver failure (ACLF) grade ≤2 treated with TERLIVAZ® plus albumin had a higher incidence of HRS reversal than those treated with placebo plus albumin1 – DUBLIN , Jan. 22, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from a retrospective analysis of three North American-centric, Phase III, randomized, placebo-controlled studies comparing the incidence of hepatorenal syndrome (HRS) reversal with baseline acute-on-chronic liver failure (ACLF) grade in adults with rapid reduction in kidney function2 treated with TERLIVAZ® plus albumin versus those treated with placebo plus albumin. Investigators will present the findings during an oral presentation at the SCCM 2023 Critical Care Congress on January 22, taking place in San Francisco, CA from January 21-24.

Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress

DUBLIN , Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023.

Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

Mallinckrodt develops and markets specialty pharmaceutical products for autoimmune and rare diseases. In my view, investors really forgot about the potential future free cash flow that Mallinckrodt could generate.

Mallinckrodt Will Likely Survive The Opioid Claims And Litigations

Mallinckrodt plc (NYSE:MNK ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller & Chief IR Officer Sigurdur Olafsson - President & CEO Bryan Reasons - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Mallinckrodt Third Quarter Earnings Annual Announcement.

Mallinckrodt plc (MNK) Q3 2022 Earnings Call Transcript

Launched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax® Strengthened Organization with Appointment of New Executives and Directors; Ordinary Shares Commenced Trading on NYSE American in October Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN , Nov. 8, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1 "We are pleased to reaffirm our 2022 guidance following solid performance in the third quarter," said Siggi Olafsson, President and Chief Executive Officer.

Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance

– Seven scientific abstracts spanning clinical and health economic outcomes research will be presented at the AASLD Liver Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function1 – DUBLIN , Nov. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and health economic outcomes research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization2 will be presented at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting in Washington, DC, from November 4-8. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS).1  Please see Limitation of Use and Important Safety Information, including Boxed Warning, below.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting

News for Mallinckrodt PLC Stock (MNK)